Global Gene Therapy for Age-related Macular Degeneration Market: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025

Report ID: BMRC 2060 | Number of pages: 197 | Publish Date: Jan 2020 | Publisher: BMRC | Category: Lifesciences and Healthcare
Our final report will cover impact analysis of COVID-19 outbreak
New

Latest research report on Gene Therapy for Age-related Macular Degeneration Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.

The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

This report focuses on the global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.

The key players covered in this study
    RetroSense Therapeutics
    REGENXBIO
    AGTC

Market segment by Type, the product can be split into
    Subretinal
    Intravitreal
    Unspecified

Market segment by Application, split into
    Monotherapy
    Combination Therapy

In this study, the years considered to estimate the market size of Gene Therapy for Age-related Macular Degeneration are as follows:
    History Year: 2014-2018
    Base Year: 2018
    Estimated Year: 2019
    Forecast Year 2019 to 2025

Market segment by Regions/Countries, this report covers
    United States
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

The study objectives of this report are:
    To analyze global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players.
    To present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by product type, market and key regions.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Interested in this report?
Get your sample now!
Table of Content
1. Chapter - Report Methodology
1.1. Research Process 
1.2. Primary Research 
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model 
1.7. USP’s of Report 
1.8. Report Description 
2. Chapter – Global Gene Therapy for Age-related Macular Degeneration Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary 
2.3. Global Gene Therapy for Age-related Macular Degeneration Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7. Gene Therapy for Age-related Macular Degeneration Market: Trends
2.8. Porter’s Five Forces Analysis
2.8.1. Bargaining Power of Suppliers
2.8.2. Bargaining Power of Consumers
2.8.3. Threat of New Entrants
2.8.4. Threat of Substitute Product and Services
2.8.5. Competitive Rivalry within the Industry
2.9. Market Attractiveness Analysis 
2.9.1. Market Attractiveness Analysis by Segmentation 
2.9.2. Market Attractiveness Analysis by Region 
3. Chapter - Global Gene Therapy for Age-related Macular Degeneration Market Overview: Quantitative Analysis
3.1. Global Gene Therapy for Age-related Macular Degeneration Market Revenue (USD Million), Market Share (%) and Growth Rate (%), 2014- 2025
3.2. Global Gene Therapy for Age-related Macular Degeneration Market Revenue Market Share (%), 2014- 2025
3.3. Global Gene Therapy for Age-related Macular Degeneration Market Sales (Number of Units), Market Share (%) and Growth Rate (%), 2014- 2025
3.4. Global Gene Therapy for Age-related Macular Degeneration Market Sales Market Share (%), 2014- 2025
4. Chapter – Global Gene Therapy for Age-related Macular Degeneration Market Analysis: Segmentation By Type
5. Chapter – Global Gene Therapy for Age-related Macular Degeneration Market Analysis: Segmentation By Application
6. Chapter - Global Gene Therapy for Age-related Macular Degeneration Market Analysis: By Manufacturer 
6.1. Global Gene Therapy for Age-related Macular Degeneration Market Revenue (USD Million), by Manufacturer, 2014 - 2025
6.2. Global Gene Therapy for Age-related Macular Degeneration Market Share (%), by Manufacturer, 2018
6.3. Global Gene Therapy for Age-related Macular Degeneration Market Sales (Number of Units), by Manufacturer, 2014 - 2025
6.4. Global Gene Therapy for Age-related Macular Degeneration Market Share (%), by Manufacturer, 2018
6.5. Global Gene Therapy for Age-related Macular Degeneration Market Price (USD/Unit), by Manufacturer, 2014 - 2025
6.6. Global Gene Therapy for Age-related Macular Degeneration Market Revenue Growth Rate (%), by Manufacturer, 2014 – 2025
6.7. Merger & Acquisition
6.8. Collaborations and Partnership
6.9. New Product Launch
7. Chapter –Gene Therapy for Age-related Macular Degeneration Market: Regional Analysis
7.1. North America
7.1.1. North America Gene Therapy for Age-related Macular Degeneration Market Revenue (USD Million) and Growth Rate (%), 2014 – 2025.
7.1.2. North America Gene Therapy for Age-related Macular Degeneration Market Revenue (USD Million) By Country, 2014 – 2025.
7.1.3. North America Gene Therapy for Age-related Macular Degeneration Revenue Market Share (%) By Country, 2014 – 2025.
7.1.4. North America Gene Therapy for Age-related Macular Degeneration Market Revenue (USD Million) and Growth Rate, By Market Segmentation, 2014 – 2025.
7.1.5. North America Gene Therapy for Age-related Macular Degeneration Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2025.
7.1.6. North America Gene Therapy for Age-related Macular Degeneration Market Sales (Number of Units) and Growth Rate (%), 2014 – 2025.
7.1.7. North America Gene Therapy for Age-related Macular Degeneration Market Sales (Number of Units) By Country, 2014 – 2025.
7.1.8. North America Gene Therapy for Age-related Macular Degeneration Sales Market Share (%) By Country, 2014 – 2025.
7.1.9. North America Gene Therapy for Age-related Macular Degeneration Market Sales (Number of Units) and Growth Rate, By Market Segmentation, 2014 – 2025.
7.1.10. North America Gene Therapy for Age-related Macular Degeneration Market Sales (Number of Units), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2025.
7.2. Europe
7.3. Asia Pacific
7.4. Latin America
7.5. Middle East & Africa
8. Chapter - Company Profiles
This free Sample Report is purely a representation of our full report, for evaluating the market scope/data and make informed purchase decisions.